0.31%QQQQ 43.45 
0.48%XLF 21.74 3.62%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
LONDON - The drugmaker AstraZeneca PLC said Wednesday it has submitted a new drug application to U.S. authorities and applied for marketing clearance from European authorities for its Onglyza diabetes treatment.
Astra made the submissions to the U.S. Food and Drug Administration and the European Medicines Agency, a significant step in what analysts consider to be a potential new blockbuster drug for the company, with its partner Bristol-Myers Squibb Co.
The program is slightly behind schedule--Astra had previously said it would submit a marketing application by the first half of the year.
The two companies began collaborating in January 2007 to develop and sell two investigational drugs for type 2 diabetes, saxagliptin and dapagliflozin.
The applications announced Wednesday are for saxagliptin, following clinical trials of the drug. Onglyza is the companies' proposed trade name.
The announcement came a day before Bristol-Myers announces its quarterly earnings results. AstraZeneca gives a third quarter update on July 31.
The above adage is well known by precious-metals investors; in fact I used this quote in one of our monthly reports. I recall how many inquiries ...
India pledged Friday not to engage in a new arms race as talks continued in Vienna over whether to let the U.S. sell India nuclear material and t...
IN THE HEADLINES McCain caps GOP convention vowing 'change is coming' to Washing...
|
Professional Website Design For Corporate - Get a Free Quote Today
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
-0.04
